1. In Vivo
  2. >>Leadership
  3. >>C-Suite Speaks

Regeneron's 'Champion Of Cancer Vaccines' Forges New Path

An Interview With Raquel Deering, Associate Director Of Immuno-Oncology At Regeneron

 
• By Brenda Sandburg

Raquel Deering, one of In Vivo's 2020 Rising Leaders, discusses Regeneron's efforts to develop combination therapies, its collaborations with cancer vaccine companies, and its plans to become a major force in the oncology field.

Magnifying lens over background with text Immuno-oncology, with the blurred lights visible in the background. 3D rendering.
• Source: Shutterstock

Raquel Deering knew she wanted to be a scientist as a young child. When she was 14, she called Paige Kaplan, a medical geneticist at The Children's Hospital of Philadelphia, and asked to visit to talk about her work. Kaplan agreed and was so impressed with Deering she took her on as an intern. For several years, Deering worked with a clinical fellow in a lab at the University of Pennsylvania and did clinical rounds with Kaplan at the hospital.

"Those super early influences in science were probably the most important," Deering said in an interview. "Science and math can...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from C-Suite Speaks

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic

 
• By David Wild

Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.

Rising Leaders 2025: Emma Hodcroft On Taking Initiative When “Plan A” Falls Short

 
• By Anabel Costa-Ferreira

Emma Hodcroft, co-founder of Pathoplexus and a key Nextstrain contributor, stresses the importance of career flexibility for young scientists. She urges early-stage researchers to embrace curiosity, using her unconventional path as an example of how curiosity can lead to impactful success. 

How Vir Bio CEO Marianne De Backer Is Rebuilding Commercial Momentum

 
• By David Wild

From billion-dollar COVID antibody to a strategic reset, Marianne De Backer is navigating Vir's comeback through pipeline focus and disciplined leadership.

More from Leadership